Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan versus placebo in idiopathic immune complex mediated membranoproliferative glomerulonephritis
NL-OMON59487Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary immune complex membranoproliferative glomerulonephritis (MPGN) comparing Iptacopan with Placebo (2 arms). Primary endpoint: Log-transformed ratio to baseline in UPCR at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on NL-OMON59487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59487.